Johnson & Johnson reported a year-over-year increase in quarterly sales of 6.7%, driven primarily by oncology drugs Darzalex and Tecvayli, which together contributed $3.2 billion in revenue. The autoimmune franchise, led by Tremfya and Skyrizi, added another $2.8 billion. Overall profit rose 8.4%, with adjusted operating margin expanding by 120 basis points as manufacturing efficiencies in the pharma segment offset higher R&D spending. Investors will note that MedTech growth of 4.1% was supported by gains in electrophysiology and robotic surgery systems.

Wall Street consensus forecasts adjusted EPS of $2.42 for the fourth quarter, a 9% increase from the prior year, on projected sales of $24.1 billion, up more than 5%. Analysts cite expectations for continuing strength in the multiple myeloma portfolio, which J&J projects will reach cumulative sales of $25 billion by 2030. Consensus growth above 5% for full-year 2025 sales underpins several recent price-target upgrades, with the median target now 15% above current levels.

While the specialty pharma pipeline remains robust, Stelara faces growing biosimilar incursions in European and U.S. psoriasis markets, with three competing products filed for approval. Management also reiterated ongoing talc litigation reserves of $3.6 billion, noting that potential settlements could impact cash flow. Investors should weigh these headwinds against a 2025 share-price gain of 43% and a dividend yield of approximately 2.4%. Finally, the 2026 guidance midpoint exceeds consensus by $600 million in sales, reinforcing expectations for continued outperformance.